PDF(Pubmed)
Abstract：
UNASSIGNED: Thyroglobulin (Tg) is a very sensitive and specific marker in patients who have undergone total thyroidectomy for papillary thyroid carcinoma (PTC). However, the presence of a Tg antibody (TgAb) interferes with Tg immunometric assays, making Tg levels unreliable indicators. There are currently no other tumor markers to monitor in patients with PTC whose serum is TgAb-positive. Thus, we investigated whether carbohydrate antigen 19-9 (CA19-9) can be used as a tumor marker for PTC.
UNASSIGNED: We retrospectively analyzed 196 consecutive patients with PTC (maximum diameter ≥ 2 cm). The serum CA19-9 and Tg values of each patient were obtained before and 0.5-1 month postsurgery. Immunohistochemical staining for PTC was performed using an antibody against CA19-9.
UNASSIGNED: High pre-surgery serum levels of CA19-9 were observed in 6.1% of the patients. Postsurgery, serum CA19-9 levels in all 196 patients decreased considerably and were within the normal range. CA19-9 expression was detected in 28 of 62 PTCs (45.2%) and was detected at various degrees and ranges in conventional PTC histology.
UNASSIGNED: Although further studies with longer follow-ups are necessary, serum CA19-9 levels may serve as a surrogate tumor marker for PTC in place of serum Tg levels sin some patients.
UNASSIGNED: We retrospectively analyzed 196 consecutive patients with PTC (maximum diameter ≥ 2 cm). The serum CA19-9 and Tg values of each patient were obtained before and 0.5-1 month postsurgery. Immunohistochemical staining for PTC was performed using an antibody against CA19-9.
UNASSIGNED: High pre-surgery serum levels of CA19-9 were observed in 6.1% of the patients. Postsurgery, serum CA19-9 levels in all 196 patients decreased considerably and were within the normal range. CA19-9 expression was detected in 28 of 62 PTCs (45.2%) and was detected at various degrees and ranges in conventional PTC histology.
UNASSIGNED: Although further studies with longer follow-ups are necessary, serum CA19-9 levels may serve as a surrogate tumor marker for PTC in place of serum Tg levels sin some patients.
摘要：
■甲状腺球蛋白（Tg）是甲状腺乳头状癌（PTC）进行甲状腺全切除术的患者中非常敏感和特异的标志物。然而,Tg抗体（TgAb）的存在会干扰Tg免疫测定，使Tg水平不可靠的指标。目前在血清为TgAb阳性的PTC患者中没有其他肿瘤标志物可监测。因此，我们研究了糖类抗原19-9(CA19-9)是否可以作为PTC的肿瘤标志物.
■我们回顾性分析了196例PTC（最大直径≥2cm）的连续患者。在手术前和术后0.5-1个月获得每位患者的血清CA19-9和Tg值。使用针对CA19-9的抗体进行PTC的免疫组织化学染色。
■在6.1%的患者中观察到高的手术前血清CA19-9水平。手术后,196例患者血清CA19-9水平显著下降,均在正常范围内.在62个PTC中的28个（45.2％）中检测到CA19-9表达，并且在常规PTC组织学中检测到不同程度和范围。
■尽管需要进一步的研究和更长时间的随访，血清CA19-9水平可以代替某些患者的血清Tg水平作为PTC的替代肿瘤标志物。
■我们回顾性分析了196例PTC（最大直径≥2cm）的连续患者。在手术前和术后0.5-1个月获得每位患者的血清CA19-9和Tg值。使用针对CA19-9的抗体进行PTC的免疫组织化学染色。
■在6.1%的患者中观察到高的手术前血清CA19-9水平。手术后,196例患者血清CA19-9水平显著下降,均在正常范围内.在62个PTC中的28个（45.2％）中检测到CA19-9表达，并且在常规PTC组织学中检测到不同程度和范围。
■尽管需要进一步的研究和更长时间的随访，血清CA19-9水平可以代替某些患者的血清Tg水平作为PTC的替代肿瘤标志物。
